NTHI (NeOnc Technologies Holdings) Research & Development: $3.93 Mil (TTM As of Mar. 2026)


NTHI NeOnc Technologies Holdings Inc NTHI
7 GF Score
Price $4.41
! 1 Warning Sign
View Full Analysis

What is NeOnc Technologies Holdings Research & Development?

NeOnc Technologies Holdings NTHI -0.90% 7 Research & Development is $3.93 Mil as of Mar. 2026. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. NeOnc Technologies Holdings's Research & Development for the three months ended in Mar. 2026 was $1.29 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $3.93 Mil.

NeOnc Technologies Holdings  (NAS:NTHI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

NeOnc Technologies Holdings Research & Development Related Terms

NeOnc Technologies Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for NeOnc Technologies Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeOnc Technologies Holdings Research & Development Chart

NeOnc Technologies Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.68 1.16 1.53 3.05 3.64

NeOnc Technologies Holdings Quarterly Data
Dec21 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 0.68 0.72 1.25 1.29
NTHI
7GF Score
NeOnc Technologies Holdings Inc NTHI
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeOnc Technologies Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $3.93 Mil mean?
NeOnc Technologies Holdings (NTHI) has a Research & Development of $3.93 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on NeOnc Technologies Holdings and its competitors.
Is NeOnc Technologies Holdings' Research & Development too high?
NeOnc Technologies Holdings' current Research & Development is $3.93 Mil. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' Research & Development compare to GUTS and PEPG?
NeOnc Technologies Holdings' Research & Development of $3.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on NeOnc Technologies Holdings and its competitors. NeOnc Technologies Holdings's current Research & Development is $3.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current Research & Development of $3.93 Mil. The current Research & Development is $3.93 Mil. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current Research & Development is $3.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeOnc Technologies Holdings Business Description

Address 23975 Park Sorrento, Suite 205, Calabasas, CA, USA, 91302
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score

Get the complete analysis for NTHI

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.41
Price